HK1037330A1 - Peg-urate oxidase conjugates and use thereof. - Google Patents

Peg-urate oxidase conjugates and use thereof.

Info

Publication number
HK1037330A1
HK1037330A1 HK01108240A HK01108240A HK1037330A1 HK 1037330 A1 HK1037330 A1 HK 1037330A1 HK 01108240 A HK01108240 A HK 01108240A HK 01108240 A HK01108240 A HK 01108240A HK 1037330 A1 HK1037330 A1 HK 1037330A1
Authority
HK
Hong Kong
Prior art keywords
peg
uricase
urate oxidase
kda
poly
Prior art date
Application number
HK01108240A
Other languages
English (en)
Inventor
L David Williams
Michael S Hershfield
Susan J Kelly
Mark G P Saifer
Merry R Sherman
Original Assignee
Mountain View Pharmaceuticals
Univ Duke
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US1999/017514 external-priority patent/WO2000007629A2/en
Application filed by Mountain View Pharmaceuticals, Univ Duke filed Critical Mountain View Pharmaceuticals
Publication of HK1037330A1 publication Critical patent/HK1037330A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0044—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on other nitrogen compounds as donors (1.7)
    • C12N9/0046—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on other nitrogen compounds as donors (1.7) with oxygen as acceptor (1.7.3)
    • C12N9/0048—Uricase (1.7.3.3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0044—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on other nitrogen compounds as donors (1.7)
    • C12N9/0046—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on other nitrogen compounds as donors (1.7) with oxygen as acceptor (1.7.3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0093—Oxidoreductases (1.) acting on CH or CH2 groups (1.17)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y107/00—Oxidoreductases acting on other nitrogenous compounds as donors (1.7)
    • C12Y107/03—Oxidoreductases acting on other nitrogenous compounds as donors (1.7) with oxygen as acceptor (1.7.3)
    • C12Y107/03003—Factor-independent urate hydroxylase (1.7.3.3), i.e. uricase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
HK01108240A 1998-08-06 2001-11-22 Peg-urate oxidase conjugates and use thereof. HK1037330A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21931898P 1998-08-06 1998-08-06
PCT/US1999/017514 WO2000007629A2 (en) 1998-08-06 1999-08-02 Peg-urate oxidase conjugates and use thereof

Publications (1)

Publication Number Publication Date
HK1037330A1 true HK1037330A1 (en) 2002-02-08

Family

ID=22818799

Family Applications (3)

Application Number Title Priority Date Filing Date
HK01108240A HK1037330A1 (en) 1998-08-06 2001-11-22 Peg-urate oxidase conjugates and use thereof.
HK07107259.4A HK1103303A1 (en) 1998-08-06 2007-07-06 A method for isolating a tetrameric uricase
HK10108340.8A HK1141738A1 (en) 1998-08-06 2010-09-02 Peg-urate oxidase conjugates and use thereof

Family Applications After (2)

Application Number Title Priority Date Filing Date
HK07107259.4A HK1103303A1 (en) 1998-08-06 2007-07-06 A method for isolating a tetrameric uricase
HK10108340.8A HK1141738A1 (en) 1998-08-06 2010-09-02 Peg-urate oxidase conjugates and use thereof

Country Status (12)

Country Link
US (11) US6576235B1 (pt)
EP (3) EP2316475B1 (pt)
CN (3) CN1264575C (pt)
AT (2) ATE498409T1 (pt)
CA (2) CA2338665C (pt)
CY (2) CY1112287T1 (pt)
DE (2) DE69943205D1 (pt)
DK (4) DK1100542T3 (pt)
ES (4) ES2361190T3 (pt)
HK (3) HK1037330A1 (pt)
PT (4) PT1588716E (pt)
ZA (1) ZA200101814B (pt)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
US20060188971A1 (en) * 1998-08-06 2006-08-24 Duke University Urate oxidase
US6783965B1 (en) * 2000-02-10 2004-08-31 Mountain View Pharmaceuticals, Inc. Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
CA2338665C (en) * 1998-08-06 2011-01-18 Mountain View Pharmaceuticals, Inc. Peg-urate oxidase conjugates and use thereof
PT1100880E (pt) 1998-08-06 2011-01-13 Univ Duke Urato-oxidase
US6913915B2 (en) * 2001-08-02 2005-07-05 Phoenix Pharmacologics, Inc. PEG-modified uricase
US7153829B2 (en) 2002-06-07 2006-12-26 Dyax Corp. Kallikrein-inhibitor therapies
EP2298278B1 (en) 2002-06-07 2015-11-11 Dyax Corp. Prevention and reduction of blood loss and inflammatory response
US20040062748A1 (en) 2002-09-30 2004-04-01 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
US8129330B2 (en) * 2002-09-30 2012-03-06 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
RS20050502A (en) * 2002-12-26 2007-08-03 Mountain View Pharmaceuticals Inc., Polymer conjugates of interferon- beta with enhanced biological potency
RS20050501A (en) * 2002-12-26 2007-08-03 Mountain View Pharmaceuticals Inc., Polymer conjugates of cytokines,chemokines,growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity
WO2004101600A2 (en) * 2003-05-12 2004-11-25 Affymax, Inc. Novel poly(ethylene glycol) modified compounds and uses thereof
ES2395413T3 (es) * 2003-05-12 2013-02-12 Affymax, Inc. Péptidos que se unen al receptor de eritropoyetina
MXPA05012314A (es) * 2003-05-12 2006-04-18 Affymax Inc Radical separador para peptido modificado con polietilenglicol.
CA3050564A1 (en) * 2003-08-29 2005-03-10 Dyax Corp. Poly-pegylated protease inhibitors
JP2008507591A (ja) * 2004-05-21 2008-03-13 ゼンコー・インコーポレイテッド 免疫原性が改変されたＣ１ｑファミリーメンバータンパク質
WO2006010005A1 (en) * 2004-06-21 2006-01-26 University Of Florida Research Foundation, Inc. Lowering uric acid to prevent or accelerate recovery of acute renal failure
US7235530B2 (en) 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
JP2008519858A (ja) * 2004-11-11 2008-06-12 アフィーマックス・インコーポレイテッド エリスロポエチンレセプターに結合する新規ペプチド
WO2006062685A2 (en) * 2004-11-11 2006-06-15 Affymax, Inc. Novel peptides that bind to the erythropoietin receptor
US8148123B2 (en) * 2005-04-11 2012-04-03 Savient Pharmaceuticals, Inc. Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase
ES2856881T3 (es) 2005-04-11 2021-09-28 Horizon Pharma Rheumatology Llc Formas variantes de urato oxidasa y su uso
EP1871877A2 (en) 2005-04-11 2008-01-02 Savient Pharmaceuticals, Inc. A variant form of urate oxidase and use thereof
US20080159976A1 (en) * 2005-04-11 2008-07-03 Jacob Hartman Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase
EP1883425A1 (en) * 2005-05-23 2008-02-06 Universite De Geneve Injectable superparamagnetic nanoparticles for treatment by hyperthermia and use for forming an hyperthermic implant
US8324159B2 (en) * 2005-06-03 2012-12-04 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
US7550433B2 (en) * 2005-06-03 2009-06-23 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
US7919461B2 (en) 2005-06-03 2011-04-05 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
ES2532804T3 (es) * 2006-04-12 2015-03-31 Crealta Pharmaceuticals Llc Purificación de proteínas con tensioactivo catiónico
CN101302501B (zh) * 2007-05-10 2012-07-04 刘国安 聚乙二醇化尿酸氧化酶化合物及其制备方法和其制剂及应用
CA2696208A1 (en) * 2007-08-21 2009-02-26 Genzyme Corporation Treatment with kallikrein inhibitors
US8273561B2 (en) * 2007-10-05 2012-09-25 Nuron Biotech, Inc. High pressure treatment of aggregated interferons
EP2271750A4 (en) * 2008-03-24 2011-07-27 Althea Technologies Inc URICASE COMPOSITIONS AND METHODS OF USE
EP2165705A1 (en) 2008-09-18 2010-03-24 Centre National de la Recherche Scientifique (CNRS) Use of a compound capable of reducing the uric acid level for the prevention and/or the treatment of lung inflammation and fibrosis
AU2010203712A1 (en) 2009-01-06 2010-07-15 Dyax Corp. Treatment of mucositis with kallikrein inhibitors
CN101875922B (zh) * 2009-04-30 2012-02-22 重庆医科大学 一种重组苛求芽孢杆菌胞内尿酸酶及其聚乙二醇修饰与应用
AU2010265964B2 (en) 2009-06-25 2014-09-18 Horizon Therapeutics Usa, Inc. Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during PEGylated uricase therapy
CN102051348B (zh) * 2009-10-27 2012-10-03 重庆富进生物医药有限公司 人源化重组尿酸酶及其突变体
LT2521568T (lt) 2010-01-06 2018-12-10 Dyax Corp. Plazmos kalikreiną surišantys baltymai
CN101928704A (zh) * 2010-03-04 2010-12-29 杭州北斗生物技术有限公司 黄曲霉尿酸氧化酶的聚乙二醇修饰物及其制备方法
US8940861B2 (en) * 2010-04-08 2015-01-27 Georgia Tech Research Corporation Variants of ancestral uricases and uses thereof
BR112013017080A8 (pt) 2011-01-06 2023-05-09 Dyax Corp Anticorpo ou fragmento funcional do mesmo que se liga a forma ativa de calicreína do plasma humano, composiçao farmacêutica e método de detecçao de calicreína do plasma em um paciente
CN102634492B (zh) 2011-02-14 2015-06-10 重庆富进生物医药有限公司 聚乙二醇化犬源尿酸氧化酶类似物及其制备方法和应用
CN102757945B (zh) * 2011-04-28 2015-03-18 杭州俊丰生物工程有限公司 人尿酸氧化酶蛋白及其制备方法和其聚乙二醇结合物
CN102827073A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
CN102260653B (zh) * 2011-06-30 2013-04-03 荣俊 一种peg化重组猪-人尿酸氧化酶融合蛋白的制备及应用方法
US9474779B2 (en) 2012-01-19 2016-10-25 Agios Pharmaceuticals, Inc. Therapeutically active compositions and their methods of use
US10481164B2 (en) 2012-03-26 2019-11-19 Amgen Inc. Method for using light scattering in real time to directly monitor and control impurity removal in purification processes
CA2917671A1 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. 2,4-or 4,6-diaminopyrimidine compounds as idh2 mutants inhibitors for the treatment of cancer
WO2015003355A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
WO2015003360A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
US9579324B2 (en) 2013-07-11 2017-02-28 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
US20150031627A1 (en) 2013-07-25 2015-01-29 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
US9968595B2 (en) 2014-03-14 2018-05-15 Agios Pharmaceuticals, Inc. Pharmaceutical compositions of therapeutically active compounds
US10428158B2 (en) 2014-03-27 2019-10-01 Dyax Corp. Compositions and methods for treatment of diabetic macular edema
US10198063B1 (en) * 2014-11-06 2019-02-05 Avago Technologies International Sales Pte. Limited Average power saving modes and power architecture for read channel product
EP3294322A4 (en) * 2015-05-15 2018-12-12 Medimmune, LLC Improved uricase sequences and methods of treatment
KR20180067658A (ko) 2015-10-15 2018-06-20 아지오스 파마슈티컬스 아이엔씨. 악성 종양의 치료를 위한 조합물 요법
MX2018004587A (es) 2015-10-15 2018-08-14 Agios Pharmaceuticals Inc Terapia de combinacion para tratar tumores malignos.
BR112018011622A2 (pt) 2015-12-11 2018-11-27 Dyax Corp método para tratar ataque de angioedema hereditário (hae) ou reduzir a taxa de ataque de hae
CN105412942B (zh) * 2015-12-23 2019-02-26 沈阳三生制药有限责任公司 聚乙二醇化的重组产朊假丝酵母尿酸氧化酶冻干注射剂
CN108103079B (zh) * 2017-06-20 2021-07-13 北京锦篮基因科技有限公司 一种高尿酸血症的基因治疗药物
JP2020530282A (ja) 2017-07-07 2020-10-22 アレナ ファーマシューティカルズ， インコーポレイテッド 組換えウリカーゼ酵素
US10980788B2 (en) 2018-06-08 2021-04-20 Agios Pharmaceuticals, Inc. Therapy for treating malignancies
WO2019241609A1 (en) * 2018-06-15 2019-12-19 Trustees Of Boston University Polypeptide compositions and methods for site-specific targeting of therapeutic agents
CN111909906B (zh) 2019-05-10 2024-04-19 重庆派金生物科技有限公司 聚乙二醇修饰的尿酸氧化酶
CN113144174B (zh) * 2020-01-22 2023-07-04 杭州远大生物制药有限公司 治疗高尿酸相关性疾病的药物
WO2022097141A1 (en) * 2020-11-03 2022-05-12 Protalix Ltd. Modified uricase and uses thereof
KR20220077590A (ko) 2020-12-02 2022-06-09 주식회사 프로앱텍 Candida Utilis 유래 요산산화효소-알부민 복합체 및 이의 제조 방법
CN115197922B (zh) * 2021-04-09 2024-05-14 派格生物医药(苏州)股份有限公司 尿酸酶或其同功异型物及其制备方法
CN114262405B (zh) * 2021-12-24 2023-02-07 浙江震东新材料有限公司 一种短链含氟防水防油剂共聚物及其制备方法
CN114813998B (zh) * 2022-03-24 2023-05-23 天津键凯科技有限公司 一种聚合物的检测方法

Family Cites Families (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE279486C (pt)
US3451996A (en) 1968-02-12 1969-06-24 Thompson Farms Co Method for the preparation of heparin
US3616231A (en) 1968-11-14 1971-10-26 Boehringer Mannheim Gmbh Process for the production of uricase
US3931399A (en) 1970-12-22 1976-01-06 Behringwerke Aktiengesellschaft Process for isolating a fibrin-stabilizing factor
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4169764A (en) 1975-08-13 1979-10-02 Ajinomoto Co., Inc. Process for production of urokinase
US4141973A (en) 1975-10-17 1979-02-27 Biotrics, Inc. Ultrapure hyaluronic acid and the use thereof
US4064010A (en) 1976-07-21 1977-12-20 Eastman Kodak Company Purification of uricase
US4301153A (en) 1977-03-21 1981-11-17 Riker Laboratories, Inc. Heparin preparation
US4425431A (en) 1978-04-20 1984-01-10 Toyo Soda Manufacturing Co., Ltd. Production of an allose-containing polysaccharide
US4312979A (en) 1978-04-20 1982-01-26 Toyo Soda Manufacturing Co., Ltd. Polysaccharides containing allose
JPS6031472B2 (ja) 1978-12-14 1985-07-22 協和醗酵工業株式会社 酸性ウリカ−ゼ
US4251431A (en) 1979-01-16 1981-02-17 Shell Oil Company Lubricating greases
JPS5599189A (en) 1979-01-22 1980-07-28 Mihama Hisaharu Modified uricase free from antigenicity and its preparation
JPS55135590A (en) 1979-04-05 1980-10-22 Mihama Hisaharu Modified asparaginase and uricase and their preparation
DE2916711A1 (de) 1979-04-25 1980-11-06 Behringwerke Ag Blutgerinnungsfaktoren und verfahren zu ihrer herstellung
FR2475900A1 (fr) 1980-02-20 1981-08-21 Fabre Sa Pierre Complexe vaccinal contenant un antigene specifique et vaccin le contenant
CH657141A5 (de) 1980-07-01 1986-08-15 Hoffmann La Roche Dns-sequenzen, rekombinante expressionsvektoren zur mikrobiellen herstellung von human-leukozyten-interferonen und transformierte mikroorganismen.
JPS5740503A (en) 1980-08-22 1982-03-06 Seikagaku Kogyo Co Ltd Separation of saccharides
FR2497006A1 (fr) 1980-12-24 1982-06-25 Ind Electro Ste Gle Contacts electriques pour cables coaxiaux et cables bifilaires
JPS57192435A (en) 1981-05-20 1982-11-26 Toyobo Co Ltd Modified polypeptide
DE3126759A1 (de) 1981-07-07 1983-01-27 Boehringer Mannheim Gmbh, 6800 Mannheim Loesliche leber-uricase, verfahren zu ihrer herstellung und verwendung
US4485176A (en) 1982-06-28 1984-11-27 E. I. Du Pont De Nemours & Company Turbidimetric method for measuring protein in urine and cerebrospinal fluid
EP0109688A3 (en) 1982-11-23 1986-12-03 The Wellcome Foundation Limited Improved complexes, processes for obtaining them and formulations containing such complexes
US4732863A (en) 1984-12-31 1988-03-22 University Of New Mexico PEG-modified antibody with reduced affinity for cell surface Fc receptors
JPH0671425B2 (ja) 1985-06-05 1994-09-14 サッポロビール株式会社 ウリカ−ゼおよびその製造法
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
WO1987000056A1 (en) 1985-06-26 1987-01-15 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4917888A (en) 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
US4847079A (en) * 1985-07-29 1989-07-11 Schering Corporation Biologically stable interferon compositions comprising thimerosal
AU597924B2 (en) 1985-12-11 1990-06-14 Natinco Nv Solubilization of protein aggregates
DD279486A1 (de) 1986-03-10 1990-06-06 Akad Wissenschaften Ddr Verfahren zur aktivierung von hydroxylgruppenhaltigen polymeren verbindungen
JPS6255079A (ja) 1986-04-23 1987-03-10 Mihama Hisaharu 修飾ウリカ−ゼ
AU612133B2 (en) 1987-02-20 1991-07-04 Natinco Nv Production of proteins in active forms
CA1305285C (en) 1987-04-21 1992-07-14 Malcolm Roy Brandon Production of proteins in active forms
AU609824B2 (en) 1987-06-15 1991-05-09 Southern Cross Biotech Pty Ltd. Production of proteins in active forms
US5080891A (en) 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US4847325A (en) 1988-01-20 1989-07-11 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
JPH01216939A (ja) 1988-02-24 1989-08-30 Hoechst Japan Kk 末熟児頭蓋内出血阻止剤
US4945086A (en) 1988-05-03 1990-07-31 The Board Of Trustees Of The Leland Stanford Junior University Smooth muscle cell growth inhibitor
US5955336A (en) 1988-08-17 1999-09-21 Toyo Boseki Kabushiki Kaisha DNA sequence for uricase and manufacturing process of uricase
US5349052A (en) 1988-10-20 1994-09-20 Royal Free Hospital School Of Medicine Process for fractionating polyethylene glycol (PEG)-protein adducts and an adduct for PEG and granulocyte-macrophage colony stimulating factor
GB8824591D0 (en) 1988-10-20 1988-11-23 Royal Free Hosp School Med Fractionation process
JP3148208B2 (ja) 1988-10-31 2001-03-19 富士ゼロックス株式会社 マルチ出力トレイ付プリントサーバおよびプリントシステム
US5324844A (en) 1989-04-19 1994-06-28 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5122614A (en) * 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5010183A (en) 1989-07-07 1991-04-23 Macfarlane Donald E Process for purifying DNA and RNA using cationic detergents
US5382518A (en) 1989-07-13 1995-01-17 Sanofi Urate oxidase activity protein, recombinant gene coding therefor, expression vector, micro-organisms and transformed cells
NZ234453A (en) 1989-07-13 1993-01-27 Sanofi Sa Recombinant dna encoding urate oxidase, and vector, host, protein and pharmaceutical compositions associated therewith
US5286637A (en) 1989-08-07 1994-02-15 Debiopharm, S.A. Biologically active drug polymer derivatives and method for preparing same
CA2065744A1 (en) 1989-08-23 1991-02-24 Zvi Fuks Wound healing preparations containing heparanase
JPH03148298A (ja) 1989-11-01 1991-06-25 Sumitomo Pharmaceut Co Ltd 修飾ペプチドおよびその製造方法
JPH03148208A (ja) 1989-11-02 1991-06-25 Mikimoto Seiyaku Kk 皮膚外用剤
US5766897A (en) 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
US5653974A (en) 1990-10-18 1997-08-05 Board Of Regents,The University Of Texas System Preparation and characterization of liposomal formulations of tumor necrosis factor
WO1992016221A1 (en) 1991-03-15 1992-10-01 Synergen, Inc. Pegylation of polypeptides
DE69233690T2 (de) 1991-07-02 2008-01-24 Nektar Therapeutics, San Carlos Abgabevorrichtung für nebelförmige Medikamente
YU66892A (sh) 1991-08-20 1995-10-24 Hoechst Ag. Fosfoinositolglikan - peptid sa delovanjem kao insulin
US5298643A (en) 1992-12-22 1994-03-29 Enzon, Inc. Aryl imidate activated polyalkylene oxides
US5321095A (en) 1993-02-02 1994-06-14 Enzon, Inc. Azlactone activated polyalkylene oxides
AU6240494A (en) 1993-02-16 1994-09-14 Enzon, Inc. Ribosome inactivating protein compositions having reduced antigenicity
US6385312B1 (en) 1993-02-22 2002-05-07 Murex Securities, Ltd. Automatic routing and information system for telephonic services
JP3875730B2 (ja) 1993-02-22 2007-01-31 サノフィ・アベンティス株式会社 自己免疫疾患の予防治療剤
US5298410A (en) 1993-02-25 1994-03-29 Sterling Winthrop Inc. Lyophilized formulation of polyethylene oxide modified proteins with increased shelf-life
US5863534A (en) 1993-04-09 1999-01-26 Bio-Technology General Corp. Polypeptide having factor Xa inhibitory method of reducing blood coagulation with a novel polypeptide having factor Xa inhibitory activity
WO1994023735A1 (en) 1993-04-09 1994-10-27 Bio-Technology General Corp. Novel polypeptide having factor xa inhibitory activity
AU6586394A (en) 1993-04-22 1994-11-08 Celtrix Pharmaceuticals, Inc. Conjugates of growth factor and bone resorption inhibitor
WO1995000162A1 (en) 1993-06-21 1995-01-05 Enzon, Inc. Site specific synthesis of conjugated peptides
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
JPH09504174A (ja) 1993-10-29 1997-04-28 インサイト ファーマシューティカルズ，インク． プロテアーゼネキシン１変異体を含むキメラ蛋白
DK0730470T3 (da) * 1993-11-10 2002-06-03 Enzon Inc Forbedrede interferonpolymerkonjugater
US5795776A (en) 1994-03-22 1998-08-18 Bio-Technology General Corp. Expression plasmids regulated by an OSMB promoter
FI96317C (fi) 1994-05-31 1996-06-10 Exavena Oy Menetelmä hienojakoisten ja muunnettujen tärkkelyksien valmistamiseksi
DE4423131A1 (de) 1994-07-01 1996-01-04 Bayer Ag Neue hIL-4-Mutantenproteine als Antagonisten oder partielle Agonisten des humanen Interleukin 4
US5633227A (en) 1994-09-12 1997-05-27 Miles, Inc. Secretory leukocyte protease inhibitor as an inhibitor of tryptase
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
WO1996017929A1 (en) 1994-12-07 1996-06-13 Novo Nordisk A/S Polypeptide with reduced allergenicity
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
IL116696A (en) 1995-01-25 1999-08-17 Bio Technology General Corp Production of enzymatically active recombinant carboxypeptidase b
JP2758154B2 (ja) * 1995-04-06 1998-05-28 エフ・ホフマン−ラ ロシユ アーゲー インターフェロンを含む液体製剤
FR2733914B1 (fr) * 1995-05-11 1997-08-01 Sanofi Sa Composition de liquide stable contenant de l'urate oxydase et composition lyophilisee pour sa preparation
JPH09154581A (ja) 1995-12-05 1997-06-17 Asahi Chem Ind Co Ltd ウリカーゼを生産する実質上純粋な微生物
US6006753A (en) 1996-08-30 1999-12-28 Eli Lilly And Company Use of GLP-1 or analogs to abolish catabolic changes after surgery
EP1007082B1 (en) 1997-01-15 2006-10-18 Phoenix Pharmacologics, Inc. Modified tumor necrosis factor
KR100369838B1 (ko) 1997-02-26 2003-09-29 주식회사 엘지생명과학 한국형c형간염바이러스의비구조단백질3에서유래한단백질분해효소단백질및그의제조방법
US6821763B2 (en) 1997-07-04 2004-11-23 Ajinomoto Co., Inc. Process for producing microbial transglutaminase
JPH1175876A (ja) 1997-07-04 1999-03-23 Ajinomoto Co Inc 新規な微生物トランスグルタミナーゼの製造法
EP1500661A1 (en) * 1998-06-01 2005-01-26 Genetech, Inc. Separation of protein monomers from aggregates by use of ion-exchange chromatography
US20060188971A1 (en) 1998-08-06 2006-08-24 Duke University Urate oxidase
US6783965B1 (en) * 2000-02-10 2004-08-31 Mountain View Pharmaceuticals, Inc. Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
CA2338665C (en) * 1998-08-06 2011-01-18 Mountain View Pharmaceuticals, Inc. Peg-urate oxidase conjugates and use thereof
JP5183836B2 (ja) 1998-08-06 2013-04-17 マウンテン ビュー ファーマシューティカルズ，インコーポレイテッド Ｐｅｇ−尿酸酸化酵素結合体およびその使用
PT1100880E (pt) 1998-08-06 2011-01-13 Univ Duke Urato-oxidase
US6425448B1 (en) * 2001-01-30 2002-07-30 Cdx Gas, L.L.P. Method and system for accessing subterranean zones from a limited surface area
RU2286711C2 (ru) 2000-02-14 2006-11-10 Фёрст Опинион Корпорэйшн Система и способ автоматической диагностики
US6913915B2 (en) 2001-08-02 2005-07-05 Phoenix Pharmacologics, Inc. PEG-modified uricase
WO2003045436A1 (en) 2001-11-28 2003-06-05 Biopolymed Inc. Biologically active non-antigenic copolymer and conjugates thereof and methods for producing the same
ZA200504990B (en) 2003-01-09 2006-08-30 Genentech Inc Purification of polypeptides
JP4273998B2 (ja) 2004-02-26 2009-06-03 学校法人東海大学 プロテオーム解析用試料の調製方法
CN103088038B (zh) 2004-07-12 2015-06-24 美国天甲生物医药有限公司 黄病毒疫苗
US20080159976A1 (en) 2005-04-11 2008-07-03 Jacob Hartman Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase
EP1871877A2 (en) 2005-04-11 2008-01-02 Savient Pharmaceuticals, Inc. A variant form of urate oxidase and use thereof
ES2856881T3 (es) 2005-04-11 2021-09-28 Horizon Pharma Rheumatology Llc Formas variantes de urato oxidasa y su uso
US8148123B2 (en) * 2005-04-11 2012-04-03 Savient Pharmaceuticals, Inc. Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase
ES2532804T3 (es) 2006-04-12 2015-03-31 Crealta Pharmaceuticals Llc Purificación de proteínas con tensioactivo catiónico
EP2100122A4 (en) 2006-11-21 2010-01-06 Univ Southern California POLY (ETHYLENE GLYCOL) ASSAYS FOR DETECTION OF ANTIBODIES AND KITS FOR CARRYING OUT SAID ASSAYS
AU2010265964B2 (en) 2009-06-25 2014-09-18 Horizon Therapeutics Usa, Inc. Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during PEGylated uricase therapy
JP5746101B2 (ja) 2012-06-18 2015-07-08 コスメディ製薬株式会社 マイクロニードルの迅速溶解法

Also Published As

Publication number Publication date
DE69925917D1 (de) 2005-07-28
CN1264575C (zh) 2006-07-19
US20100323423A1 (en) 2010-12-23
US20080031864A1 (en) 2008-02-07
CN102161984A (zh) 2011-08-24
US6576235B1 (en) 2003-06-10
CA2728907C (en) 2015-11-24
US20130052677A1 (en) 2013-02-28
PT1100542E (pt) 2005-11-30
US8618267B2 (en) 2013-12-31
HK1103303A1 (en) 2007-12-14
US20160160188A1 (en) 2016-06-09
CA2728907A1 (en) 2000-02-17
DK2158923T3 (da) 2013-03-25
EP1588716A1 (en) 2005-10-26
ZA200101814B (en) 2002-05-27
US20030166249A1 (en) 2003-09-04
US20050014240A1 (en) 2005-01-20
US20120149083A1 (en) 2012-06-14
EP2158923A1 (en) 2010-03-03
CA2338665A1 (en) 2000-02-17
EP2316475A1 (en) 2011-05-04
CN1896231A (zh) 2007-01-17
US7927589B2 (en) 2011-04-19
CN102161984B (zh) 2016-06-01
ES2245114T3 (es) 2005-12-16
ATE298251T1 (de) 2005-07-15
ES2649840T3 (es) 2018-01-15
EP2158923B1 (en) 2013-02-27
US9885024B2 (en) 2018-02-06
HK1141738A1 (en) 2010-11-19
CY1119848T1 (el) 2018-06-27
CY1112287T1 (el) 2015-12-09
PT1588716E (pt) 2011-05-25
DK1588716T3 (da) 2011-05-23
CA2338665C (en) 2011-01-18
US8067553B2 (en) 2011-11-29
DK2316475T3 (da) 2017-11-20
US20180223263A1 (en) 2018-08-09
ATE498409T1 (de) 2011-03-15
ES2404074T3 (es) 2013-05-23
CN1896231B (zh) 2012-09-05
ES2361190T3 (es) 2011-06-14
EP1588716B1 (en) 2011-02-16
PT2158923E (pt) 2013-06-04
EP2316475B1 (en) 2017-10-04
DE69925917T2 (de) 2006-05-11
DK1100542T3 (da) 2005-10-17
US20140363414A1 (en) 2014-12-11
DE69943205D1 (de) 2011-03-31
CN1322141A (zh) 2001-11-14
US20100323422A1 (en) 2010-12-23
PT2316475T (pt) 2017-12-21
US7723089B2 (en) 2010-05-25

Similar Documents

Publication Publication Date Title
CY1119848T1 (el) Απομονωμενη τετραμερικη ουρικαση
NZ509595A (en) Peg-urate oxidase conjugates and use thereof
AU2001296962A1 (en) Pegylated interleukin-10
WO2005084303A3 (en) Interferon-beta polymer conjugates
WO2001093914A3 (en) Multivalent platform molecules comprising high molecular weight polyethylene oxide
AU7761594A (en) Polyethylene glycols
CA2323048A1 (en) Poly(ethylene glycol) derivatives with proximal reactive groups
CA2304976A1 (en) Delivery of poly(ethylene glycol)-conjugated molecules from degradable hydrogels
JP2003521937A5 (pt)
HK1144701A1 (en) Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
PT1517710E (pt) Glicoformas do factor vii peguilado
HK1074802A1 (en) Bisacyloxypropylcysteine conjugates and the use thereof
CY1114005T1 (el) Συζευγματα peg-ουρικης οξειδασης και χρηση αυτων
EP1025860A3 (de) Proteinhaltige Hydrogele

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20180802